FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3092632072> ?p ?o ?g. }

• W3092632072 endingPage "1749" @default.
• W3092632072 startingPage "1739" @default.
• W3092632072 abstract "The associations between fatigue and disease activity in patients with rheumatoid arthritis (RA) have not been defined. The present objectives were to explore in RA patients the cross-sectional and longitudinal relation of fatigue with subjective as well as objective assessments of disease activity.RA patients were consecutively included when initiating biologic disease-modifying anti-rheumatic drugs (DMARDs) and assessed at baseline, 1, 2, 3, 6, and 12 months with investigation of fatigue, patient-reported outcome measures (PROMs; joint pain and patient's global disease activity, MHAQ, pain catastrophizing, Mental Health score), clinical examinations (examiner's global disease activity, 28 tender and swollen joint counts), and laboratory variables (ESR, CRP, calprotectin). Ultrasound examinations (semi-quantitative scoring (0-3)) with grey scale and power Doppler were performed of 36 joints and 4 tendons. Statistics included one-way analysis of variance, Pearson's correlations, and multiple linear and logistic regression analysis.A total of 208 RA patients (mean (SD) age 53.2 (13.2) years, disease duration 9.8 (8.5) years) were included. Fatigue levels diminished during follow-up (mean (SD) baseline/12 months; 4.8 (2.8)/3.0 (2.5) (p < 0.001)). Substantial correlations were cross-sectionally found between fatigue and PROMs (median (IQR) r=0.61 (0.52-0.71)) but not with the objective inflammatory assessments. During follow-up, baseline fatigue was associated with PROMs (p < 0.001) but not with objective inflammatory assessments. However, change of fatigue was associated with change in all variables. Higher baseline fatigue levels were associated with lower clinical composite score remission rates.Fatigue was cross-sectionally associated to subjective but not to objective disease assessments. However, change of fatigue during treatment was associated to all assessments of disease activity.Anzctr.org.au identifier ACTRN12610000284066, Norwegian Regional Committee for Medical and Health Research Ethics South East reference number 2009/1254 Key Points • In this longitudinal study of patients with established RA, fatigue was associated with patient reported outcome measures at each visit, but not with objective assessments of inflammation including calprotectin and comprehensive ultrasound examinations. • Changes in fatigue during biological treatment were associated with changes in patient reported outcome measures, clinical, laboratory and ultrasound assessments. • Baseline fatigue was associated with all patient reported outcome measures, but not objective assessments of inflammation at all the prospective visits. • Higher baseline fatigue levels were associated with lower remission rates as assessed by clinical composite scores." @default.
• W3092632072 created "2020-10-15" @default.
• W3092632072 creator A5016702384 @default.
• W3092632072 creator A5020469932 @default.
• W3092632072 creator A5026747664 @default.
• W3092632072 creator A5027107889 @default.
• W3092632072 creator A5036970733 @default.
• W3092632072 date "2020-10-11" @default.
• W3092632072 modified "2023-10-16" @default.
• W3092632072 title "Fatigue is cross-sectionally not associated with objective assessments of inflammation, but changes in fatigue are associated with changes of disease activity assessments during biologic treatment of patients with established rheumatoid arthritis" @default.
• W3092632072 cites W1588610010 @default.
• W3092632072 cites W1754935660 @default.
• W3092632072 cites W1970604933 @default.
• W3092632072 cites W2003859473 @default.
• W3092632072 cites W2028493261 @default.
• W3092632072 cites W2053086289 @default.
• W3092632072 cites W2065028487 @default.
• W3092632072 cites W2071245273 @default.
• W3092632072 cites W2096349324 @default.
• W3092632072 cites W2104136700 @default.
• W3092632072 cites W2104389209 @default.
• W3092632072 cites W2110177517 @default.
• W3092632072 cites W2115510041 @default.
• W3092632072 cites W2118771994 @default.
• W3092632072 cites W2121448756 @default.
• W3092632072 cites W2127134739 @default.
• W3092632072 cites W2127445886 @default.
• W3092632072 cites W2131111419 @default.
• W3092632072 cites W2138002544 @default.
• W3092632072 cites W2143835145 @default.
• W3092632072 cites W2154483473 @default.
• W3092632072 cites W2166031069 @default.
• W3092632072 cites W2206432491 @default.
• W3092632072 cites W2289720177 @default.
• W3092632072 cites W2411929631 @default.
• W3092632072 cites W2578522103 @default.
• W3092632072 cites W2588145460 @default.
• W3092632072 cites W2612386931 @default.
• W3092632072 cites W2613980483 @default.
• W3092632072 cites W2744603594 @default.
• W3092632072 cites W2747194850 @default.
• W3092632072 cites W2753357031 @default.
• W3092632072 cites W2793431069 @default.
• W3092632072 cites W2805210726 @default.
• W3092632072 cites W2884394222 @default.
• W3092632072 cites W2891338301 @default.
• W3092632072 cites W2905335382 @default.
• W3092632072 cites W2969449161 @default.
• W3092632072 cites W2982713431 @default.
• W3092632072 cites W3000444039 @default.
• W3092632072 cites W4249063051 @default.
• W3092632072 cites W4295125684 @default.
• W3092632072 doi "https://doi.org/10.1007/s10067-020-05402-y" @default.
• W3092632072 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8102439" @default.
• W3092632072 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33040226" @default.
• W3092632072 hasPublicationYear "2020" @default.
• W3092632072 type Work @default.
• W3092632072 sameAs 3092632072 @default.
• W3092632072 citedByCount "3" @default.
• W3092632072 countsByYear W30926320722021 @default.
• W3092632072 countsByYear W30926320722022 @default.
• W3092632072 crossrefType "journal-article" @default.
• W3092632072 hasAuthorship W3092632072A5016702384 @default.
• W3092632072 hasAuthorship W3092632072A5020469932 @default.
• W3092632072 hasAuthorship W3092632072A5026747664 @default.
• W3092632072 hasAuthorship W3092632072A5027107889 @default.
• W3092632072 hasAuthorship W3092632072A5036970733 @default.
• W3092632072 hasBestOaLocation W30926320721 @default.
• W3092632072 hasConcept C126322002 @default.
• W3092632072 hasConcept C142052008 @default.
• W3092632072 hasConcept C142724271 @default.
• W3092632072 hasConcept C151956035 @default.
• W3092632072 hasConcept C1862650 @default.
• W3092632072 hasConcept C198451711 @default.
• W3092632072 hasConcept C2776237595 @default.
• W3092632072 hasConcept C2777575956 @default.
• W3092632072 hasConcept C2779134260 @default.
• W3092632072 hasConcept C71924100 @default.
• W3092632072 hasConceptScore W3092632072C126322002 @default.
• W3092632072 hasConceptScore W3092632072C142052008 @default.
• W3092632072 hasConceptScore W3092632072C142724271 @default.
• W3092632072 hasConceptScore W3092632072C151956035 @default.
• W3092632072 hasConceptScore W3092632072C1862650 @default.
• W3092632072 hasConceptScore W3092632072C198451711 @default.
• W3092632072 hasConceptScore W3092632072C2776237595 @default.
• W3092632072 hasConceptScore W3092632072C2777575956 @default.
• W3092632072 hasConceptScore W3092632072C2779134260 @default.
• W3092632072 hasConceptScore W3092632072C71924100 @default.
• W3092632072 hasFunder F4320307765 @default.
• W3092632072 hasFunder F4320307779 @default.
• W3092632072 hasFunder F4320309117 @default.
• W3092632072 hasIssue "5" @default.
• W3092632072 hasLocation W30926320721 @default.
• W3092632072 hasLocation W30926320722 @default.
• W3092632072 hasLocation W30926320723 @default.
• W3092632072 hasLocation W30926320724 @default.
• W3092632072 hasOpenAccess W3092632072 @default.
• W3092632072 hasPrimaryLocation W30926320721 @default.

• next